JP Morgan analyst Robbie Marcus maintains Baxter International (NYSE:BAX) with a Neutral and lowers the price target from $26 to $25.
Why BAX Stock dropped -7.70% Today — RQD Quant Desk Flash
Baxter International Inc. (BAX) carries a Roarable Rating of C- (Hold) with 60/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Why BAX Stock dropped -7.70% Today — RQD Quant Desk Flash
Baxter International Inc. (BAX) dropped -7.70% to $23.50 as options desks priced 45% call premium vs. 55% put protection around the $23 max-pain magnet. Solid 30% profit margin (-2% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 54% of its 52-week range ($15.73 – $30) with RSI-14 at 37.8 (NEUTRAL RANGE).
- ▸Whale Options Positioning: $2.0M in bullish call flow vs. $2.5M in put flow (Put/Call 1.21x, implied earnings swing ±6.7%).
- ▸Fundamental Anchor: Roarable C- (Hold) backed by 30.1% gross margin and $339.0M annual free cash flow.
Healthcare company Baxter International (NYSE:BAX) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 5% year on year to $2.98 billion. Its non-GAAP profit of $0.58 per share was 11.9% abo
Wells Fargo analyst Larry Biegelsen maintains Baxter International (NYSE:BAX) with a Equal-Weight and raises the price target from $23 to $25.
Moby summary of Baxter International Inc.'s Q3 2026 earnings call
Baxter’s shares fell by over 4% on 29 October after adjusted earnings per share (EPS) dipped 16% year-over-year, despite positive revenue results.
Baxter International (NYSE:BAX) raised its full-year 2026 outlook after reporting third-quarter sales and adjusted earnings that exceeded its expectations, citing broad-based growth across its portfolio, improving execut
2026-10-30. The following slide deck was published by Baxter International Inc.
Baxter International (NYSE:BAX) received an FDA warning letter citing multiple CGMP violations at a U.S. drug manufacturing site. The FDA cited cross contamination risks and weaknesses in aseptic processing controls that
S&P 500 top movers for Oct. 29, 2026, led by CVNA and GEN among gainers and NOW and FTNT among losers.
Revenue hit $3 billion with 5% organic growth; guidance raised on momentum.
Today's Top 3 RQD Strong Buys & Whale Accumulation Setups (Live BAX Tape Review)
- ✓Live breakdown of today’s highest-scoring RQD Green-Light breakouts
- ✓1 urgent Red-Light accounting trap to cut from your watchlist immediately
- ✓Bring any ticker to live Q&A—we run it through the 5-Pillar RQD Radar on screen
BAX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +5.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BAX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BAX. Explore sector supply chains on /butterfly.
BAX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is BAX stock moving today?
Why BAX Stock dropped -7.70% Today — RQD Quant Desk Flash. Solid 30% profit margin (-2% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.